Advanced Search

Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2016 December;58(4) > Panminerva Medica 2016 December;58(4):286-93

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEPANMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Frequency: Quarterly

ISSN 0031-0808

Online ISSN 1827-1898

 

Panminerva Medica 2016 December;58(4):286-93

    REVIEWS

Management of proliferative lupus nephritis

Jose M. MONROY TRUJILLO , Derek M. FINE

Division of Nephrology, Johns Hopkins Hospital, Baltimore, MD, USA

Kidney abnormalities are present in up to 60% of patients with systemic lupus. Proliferative lupus nephritis is one of the most serious manifestation and requires rapid recognition and treatment. Kidney biopsy plays an essential role in the management and prognosis of proliferative lupus nephritis. Treatment includes and induction phase with systemic steroids and antiproliferative therapy. This is followed by a maintenance phase to prevent the risk of relapses. Cytotoxic therapy carries significant side effects and complications. Further research is needed to establish the role of biologics in the management of proliferative lupus nephritis.

language: English


FULL TEXT  REPRINTS

top of page